Category: NETs info

About NETRF

The Neuroendocrine Tumor Research Foundation (NETRF) is the leading private funder of research into causes and treatments of neuroendocrine tumors (NETs) to improve and extend the lives of those living with NETs.

Blog

Living Well with Serious Illness

Dispelling Myths about Palliative Care The goals of palliative care according to Steven Pantilat, MD, University of California, San Francisco, are pretty straightforward—to do as

Read More »
Blog

NETRF Works to Take PRRT to Next Level

https://www.youtube.com/watch?v=k1906SABias The Neuroendocrine Tumor Research Foundation (NETRF) has invested more than $1.5 million in advancing a precision form of radiation therapy for NETs called Peptide Receptor

Read More »
Blog

Lessons of NET Cancer

PRRT Patients Tell Their Stories Following the early 2018 FDA approval of the first Peptide Receptor Radionuclide Therapy (PRRT) using lutetium Lu-177 dotatate, many people are

Read More »
Blog

First PRRT Approved by U.S. FDA

New treatment for GI and pancreatic NETs The U.S. Food and Drug Administration (FDA) has approved Peptide Receptor Radionuclide Therapy (PRRT) with a new radiopharmaceutical for

Read More »
Blog

Let’s Talk About Lung NETs

Neuroendocrine tumors (NETs) are less common than other types of lung cancer but recognized with increased frequency due to advances in imaging technology and the

Read More »
Blog

PRRT for Pancreatic NETs

NETRF in collaboration with NANETS awarded the 2017 Basic Translational Science Investigator grant to Brian R. Untch, M.D., at Memorial Sloan Kettering Cancer Center for his proposal, “Enhancing Peptide Receptor Radionuclide Therapy in Well-Differentiated Pancreatic Neuroendocrine Tumors.”

Read More »